Prospective Registry Of Therapeutic EndoscopiC ulTrasound
Launched by PAOLO GIORGIO ARCIDIACONO, MD · Mar 23, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Prospective Registry Of Therapeutic Endoscopic Ultrasound (T-EUS), is studying the long-term outcomes and success rates of a special procedure called therapeutic endoscopic ultrasound. This procedure helps treat various conditions affecting the digestive system, such as blockages in the stomach or bile ducts, fluid collections in the pancreas, and infections related to pancreatitis or gallbladder issues. By gathering information on patients who undergo this treatment, researchers hope to better understand which factors can lead to successful outcomes and potential complications, ultimately helping doctors choose the best candidates for this procedure.
To be eligible for this trial, participants must be 18 years or older and be candidates for the T-EUS procedure for any of the conditions mentioned. They also need to be able to give their consent to participate. The trial is currently recruiting patients, and it welcomes individuals of all genders. If you choose to participate, you can expect to be part of a study that aims to improve treatment options for people with these serious health issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • subjects candidate to therapeutic EUS (T-EUS) procedures for any underlying disease
- • 18 years old or older
- • able to provide an informed consent to inclusion.
- Exclusion Criteria:
- • age \< 18 years
- • inability or unwillingness to sign the informed consent form (ICF)
- • contra-indication for endoscopy or use of fluoroscopy
About Paolo Giorgio Arcidiacono, Md
Dr. Paolo Giorgio Arcidiacono, MD, is a distinguished clinical trial sponsor with a robust background in medical research and patient care. With a commitment to advancing healthcare through innovative studies, Dr. Arcidiacono leads clinical trials that focus on developing effective treatments and therapies across various medical disciplines. His expertise in clinical methodologies and regulatory compliance ensures the highest standards of safety and efficacy in research. Driven by a passion for improving patient outcomes, Dr. Arcidiacono collaborates with multidisciplinary teams to foster scientific advancements and contribute to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, , Italy
Patients applied
Trial Officials
Paolo Giorgio Arcidiacono, MD, FASGE
Principal Investigator
IRCCS San Raffaele Scientific Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials